Introducing Yntradose

A radiation source brought directly to tumours.

A new direct approach to pancreatic cancer therapy

and other solid tumours

SBRT

The Challenge

The most common form of radiotherapy, Stereotactic Body Radiotherapy ('SBRT') involves focussing external radiation into tumour(s) in the body. However, collateral damage is imparted to healthy tissue in the path of the beams and organ movement significantly limits the administered dose.

More advanced Proton Beam Radiotherapy ('PBRT') greatly reduces collateral damage but its widespread adoption is heavily impaired by the cost of building treatment suites and low patient throughput. As such, these approaches are seldom used to treat abdominal organs such as the liver and pancreas.

YntraDose

The Solution

Introducing YntraDose — designed as a safe, easy-to-use, targeted and personalised radiotherapeutic treatment option for a wide range of solid tumour cancer anatomies and patient groups.

YntraDose overcomes the limitations of SBRT and PBRT whilst maximising the administered radiotherapeutic index for the patient in a single day case treatment session.

Yttrium-90

The Science

YntraDose consists of radioactive microspheres containing beta-radiating yttrium-90 (⁹⁰Y) and a biocompatible bioglue agent that, following injection, rapidly sets to form a polymerized matrix retaining the microspheres specifically at the site of injection.

Depending on the clinical setting, YntraDose can be percutaneously delivered directly to the tumour under radiological guidance or directly into a tumour bed following resection. Administration is performed under local anaesthesia by an interventional radiologist.

Expert perspectives

Leading physicians share their clinical insights on YntraDose

The impact of the clinical benefits for patients thanks to this new personalised radiotherapeutic treatment option are potentially broad.

Thanks to the targeted and localized direct intratumoural application of YntraDose, not only is the product relatively simple to use, but more importantly, there is the opportunity to reach lesions in a wide range of anatomies and therefore open the door to benefit many solid tumour cancer patient groups worldwide.

Prof. Jafar Golzarian
Prof. Jafar Golzarian
Clinical advisor, oncology

At the very beginning of the history of Interventional Oncology, ethanol injection, the only modality available at that time, was rather impressive, given that with simple percutaneous injections it allowed to achieve outcomes comparable to those of complex surgical procedures, albeit in selected cases.

The new technology of YntraDose, using Y-90, seems to be the natural evolution of the old ethanol injection, but applicable in a wide range of neoplastic diseases of different organs, with single applications and greater precision of guidance, given the great progress of imaging modalities. In summary, an actual ‘targeted therapy’ extensively feasible.

Prof. Luigi Solbiati
Prof. Luigi Solbiati
Nuclear medicine physician

Innovation

The YntraDose Solution

The YntraDose Solution comprises three key product components

YntraDose® 90

– A sterile vial containing a fixed dose and volume of Yttrium-90 microspheres.

YntraDose® Glue

– A sterile biocompatible bioglue provided as either a 2ml, 5ml or 10ml pre-filled double barrel syringe.

YntraDose® Deliver

– A sterile ‘mixing tip’ and introducer/needle.

Technology

How YntraDose works

By working closely with our clinical advisors, the YntraDose Solution has been carefully designed to provide a convenient easy-to-use and localized radiotherapy treatment for solid tumours that can be used as add-on to Standard of Care therapies.
Tailored for use by Nuclear Physicians and Interventional Radiologists, YntraDose allow to provide patients with a personalised, targeted and precise radiotherapy treatment that can be achieved on a tumour-by-tumour and patient-by-patient basis.
1

Localize

Locate lesion or tumour injection site.

2

Prepare

YntraDose-90 added to the YntraDose-Glue syringe.

3

Treat

Attached YntraDose-Deliver injection system to YntraDose Syringe.

4

Assess the outcome

Assess focalized signal of implantation of YntraDose into injection site.

Advantages of YntraDose®

Interventional radiology procedure

For users

Nuclear physicians & interventional radiologists

Easy to Use: YntraDose consists of a single percutaneous injection administered under CT guidance, delivering a fixed volume and dose to pancreatic lesions classified as unresectable locally advanced pancreatic ductal adenocarcinoma (uLA-PDAC). YntraDose is used as an adjunctive therapy in combination with standard of care (SOC) treatments such as FOLFIRINOX or gemcitabine/nab-paclitaxel

For patients

A solution exists

Safe: YntraDose is designed to avoid the need for general anaesthesia, to eliminate off-target radiation and with the ability to treat tumours near delicate organ structures

Convenient: Radiotherapy provided as a single day-case procedure as an outpatient

Minimally Invasive Procedure: Simple administration using an introducer/needle

For patients.
Healthcare providers in hospital corridor

For healthcare providers

Simple method

Accessible: Provides a radiotherapeutic treatment option in unresectable Locally Advanced PDAC where there is a huge unmet medical need

Cost Effective: No need for capital equipment and procedures are ‘non-DRG’ day-case

Protection

Intellectual
property

BetaGlue Medical possesses a wholly owned intellectual property estate across multiple jurisdictions. In addition to both granted and pending composition of matter, product by process and medical use patent claims, the company also owns a significant body of know-how. BetaGlue Medical, and YntraDose are registered trademarks of BetaGlue Technologies SpA.

Close